Alunbrig — CareFirst (Caremark)
Anaplastic large cell lymphoma (ALCL), ALK-positive
Initial criteria
- Used for initial palliative intent therapy or treatment of relapsed/refractory ALK-positive anaplastic large cell lymphoma (ALCL)
- Used as a single agent
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months